Wires·
Standing by — next sweep in ~6 min.
Markets
Dow+0.14%Russell 2000-0.31%Nasdaq-1.20%S&P 500-0.38%VXX+2.29%IEF-0.19%GLD+0.16%SLV-2.19%USO-0.33%UUP+0.27%Dow+0.14%Russell 2000-0.31%Nasdaq-1.20%S&P 500-0.38%VXX+2.29%IEF-0.19%GLD+0.16%SLV-2.19%USO-0.33%UUP+0.27%

TMO

Thermo Fisher Scientific IncHealth Careinsider_universe
Last close $700.22Nov 12, 2026
Day +0.11%

Currently held

  • Agent 20 — SIR Price/Volumelong
    4 sh @ $658.32 · stop $619.71
    +$168.12 unrealized

Everything we've seen

  1. ·Nov 15, 11:34 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  2. ·Nov 15, 11:34 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  3. ·Nov 15, 11:34 AMstreamnews

    Thermo Fisher Scientific (TMO): Cyclical Bottom Signals Re-Acceleration Toward Historical Growth

    Sound Shore Management, an investment management firm, has released its third-quarter 2026 investor letter. The letter can be downloaded here. In the quarter, the Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) declined by 1.37% and 1.34%, respectively, underperforming the Russell 1000 Value Index (up 2.61%) and the S&P 500 (up 2.30%). Over […]

  4. ·Nov 15, 11:19 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  5. ·Nov 15, 11:19 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  6. ·Nov 15, 11:04 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  7. ·Nov 15, 11:04 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  8. ·Nov 15, 10:49 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  9. ·Nov 15, 10:49 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  10. ·Nov 15, 10:34 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  11. ·Nov 15, 10:34 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  12. ·Nov 15, 10:19 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  13. ·Nov 15, 10:19 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  14. ·Nov 15, 10:04 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  15. ·Nov 15, 10:04 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  16. ·Nov 15, 9:49 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  17. ·Nov 15, 9:49 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  18. ·Nov 15, 9:34 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  19. ·Nov 15, 9:34 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  20. ·Nov 15, 9:19 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  21. ·Nov 15, 9:19 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  22. ·Nov 15, 9:04 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  23. ·Nov 15, 9:04 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  24. ·Nov 15, 8:49 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  25. ·Nov 15, 8:49 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  26. ·Nov 15, 8:34 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  27. ·Nov 15, 8:34 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  28. ·Nov 15, 8:19 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  29. ·Nov 15, 8:19 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  30. ·Nov 15, 8:04 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  31. ·Nov 15, 8:04 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  32. ·Nov 15, 7:49 AMstreamnews

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  33. ·Nov 15, 7:49 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  34. ·Nov 15, 7:34 AMstreamnews

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  35. ❖Nov 13, 4:30 PMnewsvia finnhub

    Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026

    WALTHAM, Mass., November 13, 2026--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will participate in a fireside chat hosted by UBS on Thursday, November 19th, at 8:30 a.m. (ET).

  36. ❖Nov 13, 12:25 PMnewsvia finnhub

    Should Labcorp Stock Holders Look At Quest Diagnostics Instead?

    For questions about this article or underlying research, email help@trefis.com.

  37. ❖Nov 13, 11:26 AMnewsvia finnhub

    Thermo Fisher Scientific (TMO): Cyclical Bottom Signals Re-Acceleration Toward Historical Growth

    Sound Shore Management, an investment management firm, has released its third-quarter 2026 investor letter. The letter can be downloaded here. In the quarter, the Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) declined by 1.37% and 1.34%, respectively, underperforming the Russell 1000 Value Index (up 2.61%) and the S&P 500 (up 2.30%). Over […]

  38. ❖Nov 13, 9:33 AMnewsvia finnhub

    2026 Global Screener Proficiency Testing Platform Market: $2.01 Billion Forecast for 2030 | Capitalize on AI and Cloud Demand with Thermo Fisher, Merck, Bio-Rad, and Randox

    Boost ROI with AI automation, cloud deployment, real-time analytics, system integration, accreditation support and localized software to cut costs, improve accuracy and ensure compliance.Dublin, Nov. 13, 2026 (GLOBE NEWSWIRE) -- "Screener Proficiency Testing Platform Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global screener proficiency testing platform market is experiencing rapid expansion, supported by rising demand for standardized performance evaluat

  39. ❖Nov 13, 7:05 AMnewsvia finnhub

    Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up

    TORONTO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum" or the "Company") reports its unaudited financial and operational results for the third quarter ended September 30, 2026. As of September 30, 2026, cash and cash equivalents totaled approximately US$3.56 million and digital assets totaled approximately US$8.66 million, representing combined holdings of approximately US$12.22 million, compared with US$4.12 million as of December 31, 2025 (exclu

  40. ?Nov 12, 3:15 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down ~2% today with only 30 minutes remaining until the forced close. The headlines present are largely neutral/boilerplate market research reports and a buyback-related piece that could actually support a floor or mild reversal. The macro context shows 10Y breakevens notably below trend (2.2, -1.7σ), which is modestly supportive for long-duration equities like TMO, reducing downside continuation pressure. With only 30 minutes left, there is limited runway for momentum to extend, and the buyback headline ($5B) may attract dip buyers near current levels. No clear catalysts driving the sell-off are evident in the news. The combination of limited time, potentially supportive macro (low inflation expectations benefit growth/quality names), and a buyback narrative as a potential floor argues against continuation. Probability set below 0.5 to reflect fade/stabilization bias into the close.

  41. !Nov 12, 3:15 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down ~2% today with only 30 minutes remaining until the forced close. The headlines present are largely neutral/boilerplate market research reports and a buyback-related piece that could actually support a floor or mild reversal. The macro context shows 10Y breakevens notably below trend (2.2, -1.7σ), which is modestly supportive for long-duration equities like TMO, reducing downside continuation pressure. With only 30 minutes left, there is limited runway for momentum to extend, and the buyback headline ($5B) may attract dip buyers near current levels. No clear catalysts driving the sell-off are evident in the news. The combination of limited time, potentially supportive macro (low inflation expectations benefit growth/quality names), and a buyback narrative as a potential floor argues against continuation. Probability set below 0.5 to reflect fade/stabilization bias into the close.

  42. ❖Nov 12, 1:55 PMnewsvia finnhub

    What Happened To People Who Bought Thermo Fisher Stock At A High?

    For questions about this article or underlying research, email help@trefis.com.

  43. ?Nov 12, 1:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 2.04% today, a meaningful move suggesting real selling pressure. However, several factors temper continuation confidence. The headlines present are largely neutral-to-positive: a $5B buyback announcement and sector growth reports are constructive for the stock, which may attract dip buyers and create a headwind against further downside. The macro backdrop shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend, which is favorable for long-duration assets like growth/quality names such as TMO — this reduces the macro tailwind for further selling. With 120 minutes remaining there is ample time for a reversal, and the buyback headline specifically could invite institutional accumulation near these levels. The absence of a clear negative catalyst driving the sell-off, combined with constructive buyback news and a supportive low-inflation-expectation environment, suggests the down move may fade rather than continue. Continuation probability is just below the 0.5 trigger threshold — marginally favoring no position.

  44. !Nov 12, 1:45 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 2.04% today, a meaningful move suggesting real selling pressure. However, several factors temper continuation confidence. The headlines present are largely neutral-to-positive: a $5B buyback announcement and sector growth reports are constructive for the stock, which may attract dip buyers and create a headwind against further downside. The macro backdrop shows 10-year inflation expectations (T10YIE) printing 1.7σ below trend, which is favorable for long-duration assets like growth/quality names such as TMO — this reduces the macro tailwind for further selling. With 120 minutes remaining there is ample time for a reversal, and the buyback headline specifically could invite institutional accumulation near these levels. The absence of a clear negative catalyst driving the sell-off, combined with constructive buyback news and a supportive low-inflation-expectation environment, suggests the down move may fade rather than continue. Continuation probability is just below the 0.5 trigger threshold — marginally favoring no position.

  45. ❖Nov 12, 12:59 PMnewsvia finnhub

    What Are Corning Investors Betting On?

    For questions about this article or underlying research, email help@trefis.com.

  46. ?Nov 12, 11:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 2.28% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows 10Y inflation expectations (T10YIE) printing 1.7σ below trend at 2.2, which is supportive of long-duration assets broadly — but TMO as a large-cap life sciences instruments company is not a pure long-duration play; low inflation expectations can modestly pressure pricing power narratives for equipment/reagent cycles. The absence of news means this is likely flow-driven, and flow-driven moves of this magnitude tend to persist intraday more often than not. With 250 minutes remaining (over 4 hours), there is ample time for continuation toward the close. No reversal pattern is evident from the data provided. Balancing these factors: modest continuation bias down, but no strong catalyst to push conviction above 0.55. Probability set at 0.52 — slight lean toward continuation with bounded downside given the system's stop structure.

  47. !Nov 12, 11:35 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 2.28% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The macro context shows 10Y inflation expectations (T10YIE) printing 1.7σ below trend at 2.2, which is supportive of long-duration assets broadly — but TMO as a large-cap life sciences instruments company is not a pure long-duration play; low inflation expectations can modestly pressure pricing power narratives for equipment/reagent cycles. The absence of news means this is likely flow-driven, and flow-driven moves of this magnitude tend to persist intraday more often than not. With 250 minutes remaining (over 4 hours), there is ample time for continuation toward the close. No reversal pattern is evident from the data provided. Balancing these factors: modest continuation bias down, but no strong catalyst to push conviction above 0.55. Probability set at 0.52 — slight lean toward continuation with bounded downside given the system's stop structure.

  48. ❖Nov 12, 11:12 AMnewsvia finnhub

    Is Thermo Fisher Scientific (TMO) Reasonable After Its $5 Billion Buyback?

    Thermo Fisher Scientific has delivered strong share price gains in recent years, and the latest news around capital returns puts its cash generation firmly in focus. For anyone tracking the stock, the key question is whether that recent performance lines up with what the business can produce in cash flows over time. Over the past 3 years, Thermo Fisher Scientific has returned 54.0%, which puts meaningful expectations on the company to keep turning its operations into robust cash flows. The...

  49. ?Nov 12, 10:15 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down ~1.90% today with no attributable headline catalyst visible, suggesting this is likely macro or sector-driven selling rather than idiosyncratic news. The macro context shows T10YIE at 1.7σ below its 24-month trend (2.2%), indicating inflation expectations are suppressed and real yields are relatively elevated — a modestly negative backdrop for high-multiple, long-duration sensitive names like TMO (a large-cap life sciences/instruments company trading at premium valuations). With 330 minutes remaining (essentially a full trading session still ahead), there is ample time for the move to continue if selling pressure persists. However, at ~1.9% down, TMO is approaching but not yet at a magnitude that typically triggers aggressive mean-reversion buying. No news catalyst to explain the move suggests this is flow-driven, which can persist. The absence of a reversal signal or volume concern tips the edge marginally toward continuation. Probability is modest rather than high given: (1) no clear news driver reducing conviction in directionality, (2) the macro read is supportive of the downside thesis but not decisively so, and (3) TMO at these levels may attract value-oriented buyers into the close. Overall, a slight lean toward continued downside is warranted.

  50. !Nov 12, 10:15 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down ~1.90% today with no attributable headline catalyst visible, suggesting this is likely macro or sector-driven selling rather than idiosyncratic news. The macro context shows T10YIE at 1.7σ below its 24-month trend (2.2%), indicating inflation expectations are suppressed and real yields are relatively elevated — a modestly negative backdrop for high-multiple, long-duration sensitive names like TMO (a large-cap life sciences/instruments company trading at premium valuations). With 330 minutes remaining (essentially a full trading session still ahead), there is ample time for the move to continue if selling pressure persists. However, at ~1.9% down, TMO is approaching but not yet at a magnitude that typically triggers aggressive mean-reversion buying. No news catalyst to explain the move suggests this is flow-driven, which can persist. The absence of a reversal signal or volume concern tips the edge marginally toward continuation. Probability is modest rather than high given: (1) no clear news driver reducing conviction in directionality, (2) the macro read is supportive of the downside thesis but not decisively so, and (3) TMO at these levels may attract value-oriented buyers into the close. Overall, a slight lean toward continued downside is warranted.

  51. ❖Nov 12, 10:11 AMnewsvia finnhub

    Thermo Fisher Scientific (TMO), Why Is It Back In The Spotlight?

    Thermo Fisher Scientific (TMO) is drawing fresh attention after recent coverage highlighted its role as a key supplier in cell sheet based gene therapy, further extending its reach into regenerative medicine applications. The recent gene therapy attention comes on top of a strong run in Thermo Fisher Scientific's stock. The 30 day share price return is 8.38%, and the 90 day move is 20.44%. This points to building momentum supported by a 1 year total shareholder return of 22.48% and 54.01%...

  52. ❖Nov 12, 10:01 AMnewsvia finnhub

    Cell Culture Protein Surface Coating - Global Strategic Business Report 2026: Capitalize on the $2.1B Market by 2032 as Corning, Merck, Sartorius and Thermo Fisher Accelerate Competition

    Dublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Cell Culture Protein Surface Coating - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell culture protein surface coating market was valued at US$730 million in 2025 and is projected to reach US$2.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 16.7%. Market growth is being supported by advances in cell-based research, rising biopharmaceutical production, increased adoption

  53. ❖Nov 12, 10:00 AMnewsvia finnhub

    Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck

    Capitalize on demand for automated, high-throughput and single-cell solutions, driven by personalized medicine, proteomics, genomics and biopharma researchDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell lysis and cell fractionation market was valued at US$2.8 billion in 2025 and is projected to reach US$4.5 billion by 2032, expanding at a compound annual growth

  54. ❖Nov 12, 9:54 AMnewsvia finnhub

    Single-Use Bioprocessing - Global Strategic Business Report 2026: Capitalize on 13.4% CAGR to $47.7B by 2032, Featuring Profiles of Danaher, Thermo Fisher Scientific, 3M, and Eppendorf

    Dublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Single-Use Bioprocessing - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-use bioprocessing market was valued at US$19.8 billion in 2025 and is projected to reach US$47.7 billion by 2032, expanding at a compound annual growth rate (CAGR) of 13.4% during the forecast period. Market growth is supported by rising demand for biologics, vaccines, biosimilars, monoclonal antibodies, therapeutic pr

  55. ❖Nov 12, 12:00 AMnewsvia finnhub

    Biomatter Raises $18M Series A to Scale Its AI-Powered Enzyme Design for Global Industry Leaders

    VILNIUS, Lithuania, November 12, 2026--Biomatter, the custom enzyme design company, today announced the closing of an oversubscribed $18 million Series A financing led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet.

  56. ❖Nov 11, 4:34 PMnewsvia finnhub

    Could You Have Seen The Run In Guardant Health Stock Coming?

    For questions about this article or underlying research, email help@trefis.com.

  57. ❖Nov 11, 10:29 AMnewsvia finnhub

    Is Illumina Stock Worth The Wait?

    For questions about this article or underlying research, email help@trefis.com.

  58. ❖Nov 11, 9:44 AMnewsvia finnhub

    Global Biotechnology Market to Reach $5 Trillion by 2032, Driven by Biopharmaceuticals, Gene Editing and Sustainable Innovation | Features Profiles of Danaher, Roche, Illumina, Merck, Thermo Fisher and More

    Target biopharma, gene editing and sustainable agriculture; leverage regional and competitive insights to uncover revenue opportunities and guide R&D investmentDublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Biotechnology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global biotechnology market was valued at US$2.1 trillion in 2025 and is projected to reach US$5.0 trillion by 2032, expanding at a compound annual growth rate (CAGR) of 13.3%. Market growth

  59. ❖Nov 11, 9:42 AMnewsvia finnhub

    Mass Spectrometry - Global Strategic Business Report 2026-2032 Featuring Thermo Fisher, Agilent, Bruker, Shimadzu, Waters and More

    Capitalize on demand for high-sensitivity MS, hybrid LC-MS/GC-MS platforms, and software-led services across biopharma, diagnostics, food safety and environmental testingDublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Mass Spectrometry - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global mass spectrometry market was valued at US$2.3 billion in 2025 and is projected to reach US$3.3 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.1%

  60. ❖Nov 11, 9:21 AMnewsvia finnhub

    Transfection Technologies - Global Strategic Business Report 2026: Capitalize on a $2.5 Billion Market by 2032 as Thermo Fisher, Lonza, Bio-Rad, Qiagen and MilliporeSigma Accelerate

    Target equipment and gene-editing delivery opportunities, using regional and competitive insights to prioritize R&D, partnerships and revenue growth.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Transfection Technologies - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global transfection technologies market was valued at US$1.3 billion in 2025 and is projected to reach US$2.5 billion by 2032, expanding at a compound annual growth rate (CAGR) of 9.4%

  61. ❖Nov 11, 9:20 AMnewsvia finnhub

    Whole Exome Sequencing - Global Strategic Business Report 2026: Capitalize on 19.5% CAGR to $2.3 Billion by 2032 as Illumina, Thermo Fisher Scientific, BGI Genomics, and QIAGEN Accelerate

    Target WES opportunities in precision medicine, rare diseases and oncology, using scalable sequencing, AI analytics and user-friendly bioinformatics to cut costs and accelerate adoption.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Whole Exome Sequencing - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global whole exome sequencing market was valued at US$648 million in 2025 and is projected to reach US$2.3 billion by 2032, expanding at a compound an

  62. ❖Nov 11, 9:18 AMnewsvia finnhub

    Single-Cell Analysis - Global Strategic Business Report 2026: Capitalize on 20.4% CAGR as Illumina, Thermo Fisher Scientific, Bio-Rad and Agilent Battle for Shares in the $26.1 Billion Market by 2032

    Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Single-Cell Analysis - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global single-cell analysis market was valued at US$7.1 billion in 2025 and is projected to reach US$26.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 20.4%. Growth is being supported by increasing demand for precision medicine, targeted therapies, biomarker discovery and advanced cellular research across pharma

  63. ❖Nov 11, 9:15 AMnewsvia finnhub

    Human Identification - Global Strategic Business Report 2026: Capitalize on 10.1% CAGR to $1.9 Billion by 2032 | Thermo Fisher, Illumina, Qiagen and Bio-Rad Vie for Shares

    Target revenue opportunities in rapid DNA, NGS, multimodal biometrics and personalized medicine, guided by regional, segment and competitive intelligenceDublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Human Identification - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global human identification market was valued at US$950.1 million in 2025 and is projected to reach US$1.9 billion by 2032, expanding at a compound annual growth rate (CAGR) of 10.1%. M

  64. ❖Nov 11, 9:14 AMnewsvia finnhub

    Genomics - Global Strategic Business Report 2026: Capitalize on the $117.3 Billion Market by 2032, Featuring Strategic Intelligence on Illumina, Thermo Fisher Scientific, Danaher, and Oxford Nanopore

    Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Genomics - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global genomics market was valued at US$45.7 billion in 2025 and is projected to reach US$117.3 billion by 2032, expanding at a compound annual growth rate (CAGR) of 14.4%. Market growth is being supported by advances in next-generation sequencing (NGS), bioinformatics, artificial intelligence, gene editing and precision medicine, alongside expandi

  65. ❖Nov 11, 9:12 AMnewsvia finnhub

    Epigenetics - Global Strategic Business Report: Capitalize on an 18.2% CAGR to Secure the $5.5 Billion 2030 Market as Illumina, Thermo Fisher Scientific, Qiagen, and Bio-Rad Disrupt Precision Medicine

    Target epigenetics kits, precision oncology and AI-enabled sequencing; leverage tariff, regional and competitive insights to optimize sourcing and unlock revenue.Dublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Epigenetics - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Epigenetics Market Forecast to Reach US$5.5 Billion by 2030 The global epigenetics market was valued at US$2 billion in 2024 and is projected to reach US$5.5 billion by 2030, expanding at

  66. ❖Nov 10, 9:16 PMnewsvia finnhub

    Thermo Fisher Scientific (TMO) Is A Key Supplier In Cell Sheet Gene Therapy

    Thermo Fisher Scientific (NYSE:TMO) is emerging as a key supplier in the global cell sheet-based gene therapy market, which is gaining attention in regenerative medicine in 2026. Sector milestones in cell sheet-based therapies for tissue repair and organ regeneration have highlighted Thermo Fisher Scientific's tools, platforms, and services used by developers in this field. Thermo Fisher Scientific's involvement in cell sheet technologies extends the business further into advanced gene and...

  67. ❖Nov 10, 8:40 PMnewsvia finnhub

    Ingersoll Rand Vs Hubbell: Which Stock Is The Better Buy?

    For questions about this article or underlying research, email help@trefis.com.

  68. ❖Nov 10, 11:00 AMnewsvia finnhub

    Thermo Fisher Scientific (TMO) Is Benefiting From More Than Healthcare Demand: Here’s the Overlooked AI Connection

    Liontrust Investment Partners recently released its “GF Global Dividend Fund” Q3 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned -0.6% in the third quarter of 2026, underperforming the MSCI AC World Index, which gained 1.6%. However, the Fund remained ahead of the benchmark year to date, with a […]

  69. ❖Nov 10, 10:09 AMnewsvia finnhub

    Electrophoresis Reagents - Global Strategic Business Report: Capitalize on China's 7.4% CAGR as Bio-Rad, QIAGEN, Agilent, Merck Millipore and Thermo Fisher Battle for $1.3B by 2032

    Automation, precast gels and eco-friendly dyes improve speed and accuracy, while genomics, diagnostics and personalized medicine fuel demand.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Electrophoresis Reagents - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Electrophoresis Reagents Market to Reach US$1.3 Billion by 2032 as Genomics and Molecular Diagnostics Expand The global electrophoresis reagents market was valued at US$1 billion in 2025 and is p

  70. ❖Nov 10, 10:02 AMnewsvia finnhub

    Nucleic Acid Isolation and Purification - Global Strategic Business Report: Capture the $3.9 Billion Revenue Surge by 2030 as Thermo Fisher, Qiagen, Danaher, Illumina, and Bio-Rad Battle for Share

    Target automation, magnetic bead and microfluidic platforms for diagnostics, genomics and precision medicine; use tariff insights to optimize sourcing and supply chains.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Nucleic Acid Isolation and Purification - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global Nucleic Acid Isolation and Purification Market to Reach US$12 Billion by 2030 The global nucleic acid isolation and purification market was valued at US

  71. ❖Nov 10, 10:00 AMnewsvia finnhub

    Nucleic Acid Labeling - Global Strategic Business Report 2026: Secure Share of a $2.8 Billion Market by 2032 as Thermo Fisher Scientific, Roche, Merck, and Agilent Accelerate Genomics

    Target genomics and diagnostics with automated, high-throughput fluorescent labeling that boosts accuracy, scalability and lab efficiency.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Nucleic Acid Labeling - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. Global Nucleic Acid Labeling Market to Reach US$2.8 Billion by 2032 The global nucleic acid labeling market was valued at US$1.7 billion in 2025 and is projected to reach US$2.8 billion by 2032, expandin

  72. ❖Nov 10, 9:58 AMnewsvia finnhub

    In Vitro Toxicology Testing - Global Strategic Business Report: Capitalize on the $14B-to-$27.4B Surge as Thermo Fisher Scientific, Merck, Eurofins and Bio-Rad Disrupt Testing by 2032

    Cut costs and accelerate safety assessments with human-relevant in vitro models, AI, organ-on-chip and high-throughput screening amid regulatory and ethical shifts.Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "In Vitro Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global in vitro toxicology testing market was valued at US$14 billion in 2025 and is projected to reach US$27.4 billion by 2032, expanding at a compound annual growth rate

  73. ❖Nov 10, 9:24 AMnewsvia finnhub

    Gene Panels - Global Strategic Business Report 2026: Capitalize on 17.9% CAGR as Market Triples to $12.6B by 2032 - Track Key Players Illumina, Roche, QIAGEN, Thermo Fisher, Agilent and More

    Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Gene Panel - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global gene panel market, valued at US$4 billion in 2025, is projected to reach US$12.6 billion by 2032, expanding at a compound annual growth rate (CAGR) of 17.9%. Market growth is being supported by advances in next-generation sequencing (NGS), increasing adoption of personalized medicine, rising demand for early disease detection and the growi

  74. ❖Nov 10, 9:14 AMnewsvia finnhub

    Global DNA and Genomic Profiling Kits Market Report 2026 | Capture the $2.09B Market by 2030 | Features Profiles of Thermo Fisher, Illumina, QIAGEN and More

    Dublin, Nov. 10, 2026 (GLOBE NEWSWIRE) -- "Deoxyribonucleic Acid (DNA) and Genomic Profiling Kits Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global deoxyribonucleic acid (DNA) and genomic profiling kits market is experiencing rapid growth as healthcare providers, research organizations and forensic laboratories expand their use of advanced genetic testing technologies. The market is projected to increase from $1.28 billion in 2025 to $1.41 billion in 2026, repre

  75. ?Nov 9, 3:21 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 3.48% today, a meaningful move suggesting real institutional flow. However, with only 25 minutes remaining until the forced close, the time window is very constrained — insufficient runway to reach the +3% profit target from current levels without an additional significant push. The news backdrop consists entirely of generic market research report press releases mentioning Thermo Fisher alongside many competitors; these are boilerplate reports that rarely drive sustained price action and provide no catalyst clarity. The macro context (elevated mortgage rates) is sector-neutral for life sciences/instruments. With the stock already extended 3.48% and so little time left, late-session profit-taking or mean reversion is a real risk. The tight time window is the primary disqualifier here — even a solid momentum setup struggles to justify continuation when there are only 25 minutes to work with and the move is already mature. Probability falls just below the 0.5 trigger threshold.

  76. !Nov 9, 3:21 PMsignalseverity 0.03

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 3.48% today, a meaningful move suggesting real institutional flow. However, with only 25 minutes remaining until the forced close, the time window is very constrained — insufficient runway to reach the +3% profit target from current levels without an additional significant push. The news backdrop consists entirely of generic market research report press releases mentioning Thermo Fisher alongside many competitors; these are boilerplate reports that rarely drive sustained price action and provide no catalyst clarity. The macro context (elevated mortgage rates) is sector-neutral for life sciences/instruments. With the stock already extended 3.48% and so little time left, late-session profit-taking or mean reversion is a real risk. The tight time window is the primary disqualifier here — even a solid momentum setup struggles to justify continuation when there are only 25 minutes to work with and the move is already mature. Probability falls just below the 0.5 trigger threshold.

  77. ❖Nov 9, 2:03 PMnewsvia finnhub

    5 Best All-Time High Stocks to Buy According to Wall Street

    Wall Street’s leadership changed hands over the past month. The technology and chip stocks that carried the market through most of 2026 lost ground, while healthcare, financials, real estate, utilities and consumer-focused stocks took over. The scoreboard showed it in mid-October. Healthcare led gains among the S&P 500’s 11 sectors and hit a record high, […]

  78. ❖Nov 9, 9:33 AMnewsvia finnhub

    Global Genome Annotation Services Market Report 2026: Trends and Forecast to 2030 | Capitalize on AI and Precision Medicine with Roche, Thermo Fisher, Illumina, QIAGEN

    Boost ROI via automated AI annotation, cloud infrastructure, regional data centers, scalable multi-omics services, high-quality curation and strategic acquisitions.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Genome Annotation Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global genome annotation services market is experiencing rapid growth as pharmaceutical companies, biotechnology organizations, clinical laboratories, and research institutions increase the

  79. ❖Nov 9, 9:32 AMnewsvia finnhub

    Global Clinical Genomics Software Market Report 2026 | Capitalize on 14.8% CAGR Through 2030 as Google, Microsoft, NVIDIA and Illumina Scale AI, Cloud and Precision Medicine

    Players: Google, Microsoft, AWS, NVIDIA and Thermo Fisher. Profiled: clinical genomics software competitors, services, trends, regional shares and opportunities.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Clinical Genomics Software Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global clinical genomics software market is experiencing rapid expansion, supported by advances in genomic testing, bioinformatics, precision medicine, and cloud-based healthcare techno

  80. ❖Nov 9, 9:30 AMnewsvia finnhub

    Kinase Drug Discovery Solutions Market Report 2026 | Capture 7.5% CAGR Through 2030 as Thermo Fisher, Eurofins, GenScript, and Sino Biological advance AI and precision oncology

    Boost ROI through AI target discovery, high-throughput screening, integrated medicinal chemistry, pharma-CRO partnerships, local reagent production and cost-efficient digital workflows.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Kinase Drug Discovery Solutions Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global kinase drug discovery solutions market is experiencing strong growth, supported by expanding oncology research, rising pharmaceutical research and developme

  81. ❖Nov 9, 9:26 AMnewsvia finnhub

    Genomic Variant Prioritization Artificial Intelligence (AI) Global Market Report 2026 | Capitalize on 26.5% CAGR with Illumina, QIAGEN, Thermo Fisher Scientific and Tempus AI

    Boost ROI with scalable cloud analytics, automated variant filtering, multi-omics integration and explainable clinical tools; reduce tariff exposure through domestic infrastructure.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Genomic Variant Prioritization AI Global Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global genomic variant prioritization artificial intelligence (AI) market is experiencing rapid expansion as healthcare providers, researchers, and life scien

  82. ❖Nov 9, 9:25 AMnewsvia finnhub

    Global Ribonucleic Acid (RNA) Extraction Kits Market Report 2026 | Capitalize on 10.1% CAGR to $3.68B by 2030 as Roche, Thermo Fisher, QIAGEN and Merck Accelerate Automation

    Boost ROI with automated, high-throughput magnetic-bead extraction, cost-optimized formats, and portable kits that improve accuracy, scalability, and lab efficiency.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Ribonucleic Acid (RNA) Extraction Kits Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. The global ribonucleic acid (RNA) extraction kits market is experiencing rapid growth, supported by expanding genomic research, increased molecular diagnostic testing and co

  83. ❖Nov 9, 9:11 AMnewsvia finnhub

    Deoxyribonucleic Acid (DNA) Profiling Kits Market Report 2026-2030 | Capitalize on 12.2% CAGR as Thermo Fisher Scientific, Illumina, QIAGEN and Promega Drive NGS, AI and Automation

    Boost ROI through multiplex PCR, NGS, automation, AI/cloud analysis and DTC testing; use acquisitions to expand capabilities and reduce turnaround time and reagent use.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Deoxyribonucleic Acid (DNA) Profiling Kits Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global deoxyribonucleic acid (DNA) profiling kits market is experiencing rapid growth as demand increases across forensic science, personalized medicine, genetic diagnos

  84. ❖Nov 9, 9:10 AMnewsvia finnhub

    Global Release Testing for Gene Therapy Market Report 2026 | Capitalize on 16.5% CAGR Through 2030 as Thermo Fisher, Lonza, Eurofins and WuXi AppTec Accelerate Automated QC

    Boost ROI with automated rapid-release analytics, digital PCR and sensitive assays; expand contract testing and localize sourcing to reduce tariff costs and delays.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Release Testing for Gene Therapy Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global release testing for gene therapy market is experiencing rapid growth as gene therapy development accelerates and regulatory authorities increase their focus on product quality,

  85. ❖Nov 9, 9:09 AMnewsvia finnhub

    Global Arrayed CRISPR Screening Market Report 2026 | Capitalize on 17.7% CAGR to $3.43 Billion as Thermo Fisher, Merck, Agilent and GenScript Advance Precision Drug Discovery

    Boost ROI through partnerships, automation, custom screening, bioinformatics, and local reagent and equipment production to cut costs and accelerate target validation.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Arrayed Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Screening Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global arrayed clustered regularly interspaced short palindromic repeats (CRISPR) screening market is experiencing rapid expansi

  86. ❖Nov 9, 9:07 AMnewsvia finnhub

    Cell Sheet-Based Gene Therapy Global Market Report 2026 | Capitalize on 14.6% CAGR as Hitachi, Thermo Fisher, Fujifilm, Lonza and Abeona Scale Localized Regeneration

    Boost ROI through gene-corrected cell sheets, localized manufacturing, precision regenerative therapies, and expansion into oncology and cardiology.Dublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Cell Sheet-Based Gene Therapy Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global cell sheet-based gene therapy market is experiencing rapid growth, supported by advances in tissue engineering, gene delivery technologies and regenerative medicine research. The market is projec

  87. ❖Nov 9, 7:20 AMnewsvia finnhub

    Should You Continue to Hold TMO Stock in Your Portfolio?

    Thermo Fisher's accelerating organic growth, rising bioproduction demand and strong capital returns support its outlook, but macroeconomic risks and competition remain concerns.

  88. ❖Nov 9, 6:00 AMnewsvia finnhub

    Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting

    New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for clinical laboratoriesLOUISVILLE, Colo., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced it will present new data from its tumor-informed and tumor-naïve molecular monitoring programs at the Association for Molecular Pathology (AM

  89. ❖Nov 8, 10:42 AMnewsvia finnhub

    Democrats Win Midterms: 5 Best Healthcare and Insurance Stocks To Buy

    Healthcare stocks emerged as some of the clearest beneficiaries of the Democrats’ sweeping victory in the November 3 midterm elections, as investors reassessed the outlook for federal healthcare spending. With Democrats gaining control of both the House and Senate, expectations of potential changes to Medicaid funding and Affordable Care Act subsidies helped fuel a rally […]

  90. ❖Nov 7, 6:14 PMnewsvia finnhub

    What Does Thermo Fisher Scientific (TMO) Mean By A New $5 Billion Buyback?

    Thermo Fisher Scientific (NYSE:TMO) approved a new US$5b share repurchase program, replacing its prior authorization. The refreshed buyback plan gives the life sciences group additional capacity to retire stock through future share repurchases. The new authorization indicates Thermo Fisher Scientific intends to continue returning capital to shareholders through ongoing share repurchase activity. There is more to Thermo Fisher Scientific than the newly approved US$5b share repurchase program...

  91. ❖Nov 6, 8:10 PMnewsvia finnhub

    How IDEXX Stock Is Engineered To Make Money For You

    For questions about this article or underlying research, email help@trefis.com.

  92. ?Nov 6, 3:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 2.38% today, a meaningful move suggesting real institutional flow. However, with only 35 minutes remaining until the forced close cutoff, the time window is very compressed and limits the opportunity for further meaningful continuation. The lone headline is a generic market research report on oligonucleotide synthesis — not a catalyst specific enough to sustain momentum into the close. The macro context (elevated mortgage rates) is sector-neutral for life sciences/instruments and provides no tailwind. With limited time remaining, the risk of end-of-day profit-taking or mean reversion in a stock that has already moved 2.38% is real. The setup does not meet the threshold for a continuation trade given the time constraint overriding what would otherwise be a borderline momentum signal.

  93. !Nov 6, 3:10 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 2.38% today, a meaningful move suggesting real institutional flow. However, with only 35 minutes remaining until the forced close cutoff, the time window is very compressed and limits the opportunity for further meaningful continuation. The lone headline is a generic market research report on oligonucleotide synthesis — not a catalyst specific enough to sustain momentum into the close. The macro context (elevated mortgage rates) is sector-neutral for life sciences/instruments and provides no tailwind. With limited time remaining, the risk of end-of-day profit-taking or mean reversion in a stock that has already moved 2.38% is real. The setup does not meet the threshold for a continuation trade given the time constraint overriding what would otherwise be a borderline momentum signal.

  94. ❖Nov 6, 9:25 AMnewsvia finnhub

    Global Oligonucleotide Synthesis Services Market Report 2026 | Capitalize on $4.7B by 2030 as Thermo Fisher, Agilent, QIAGEN and IDT Accelerate GMP and CRISPR Capacity

    Boost ROI via low-scale custom oligos, reduced waste, rapid turnaround, seamless scaling, regional sourcing, and distribution partnerships.Dublin, Nov. 06, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Synthesis Services Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global oligonucleotide synthesis services market is experiencing strong growth as demand increases across genomics, molecular diagnostics, gene editing and nucleic acid therapeutics. The market expanded fro

  95. ❖Nov 6, 6:21 AMnewsvia finnhub

    Thermo Fisher Scientific Authorizes $5 Billion Share Buyback after Upbeat Earnings

    Thermo Fisher Scientific announces new $5 billion share buyback authorization, as traders balance broader market gains against capital plans.

  96. ❖Nov 6, 6:06 AMnewsvia finnhub

    Capital Group Growth (CGGR) Buys $16.8 Million More Seagate on Nov. 4

    The ETF bought $16.8 million of Seagate and $10.4 million of Meta while selling $119.5 million of Apple on Wednesday.

  97. ?Nov 5, 2:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 3.11% intraday, a meaningful move suggesting real selling pressure. However, several factors argue against continuation: (1) The most recent headline ('Improving Biopharma Spending Lifts Thermo Fisher') is explicitly positive and timestamped late in the session, suggesting a potential sentiment shift or at minimum a counter-narrative emerging that could attract dip buyers. (2) The other headlines are neutral market-report type content, not adding further negative pressure. (3) With 85 minutes remaining, there is time for a reversal, but the positive headline near session end is the key concern — it may catalyze short covering or institutional buying into the close. (4) The macro context (elevated DFF) is modestly negative for growth/biopharma names but is not a strong directional driver for TMO specifically. (5) A 3.11% down move without a clearly negative catalyst visible in the headlines raises the possibility this was an overreaction or sector rotation flush that could partially retrace. The late positive headline is a meaningful fade signal, pushing probability below 0.5.

  98. !Nov 5, 2:20 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 3.11% intraday, a meaningful move suggesting real selling pressure. However, several factors argue against continuation: (1) The most recent headline ('Improving Biopharma Spending Lifts Thermo Fisher') is explicitly positive and timestamped late in the session, suggesting a potential sentiment shift or at minimum a counter-narrative emerging that could attract dip buyers. (2) The other headlines are neutral market-report type content, not adding further negative pressure. (3) With 85 minutes remaining, there is time for a reversal, but the positive headline near session end is the key concern — it may catalyze short covering or institutional buying into the close. (4) The macro context (elevated DFF) is modestly negative for growth/biopharma names but is not a strong directional driver for TMO specifically. (5) A 3.11% down move without a clearly negative catalyst visible in the headlines raises the possibility this was an overreaction or sector rotation flush that could partially retrace. The late positive headline is a meaningful fade signal, pushing probability below 0.5.

  99. ?Nov 3, 10:20 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 2.05% today with no single attributable headline driving the move, suggesting underlying institutional flow rather than a headline-driven pop that might fade. The move is meaningful in magnitude but sits at the lower end of the 2-5% range, indicating moderate rather than strong conviction. With 325 minutes remaining (~5.4 hours), there is ample time for continuation if momentum holds, which is a positive factor. However, several headwinds temper enthusiasm: (1) macro context shows DFF running 2.2σ above trend, which is a tightening signal that pressures growth/life-sciences names like TMO; (2) one headline flags TMO as among '3 S&P 500 stocks we find risky,' which could weigh on sentiment or attract short interest; (3) no clearly bullish catalyst is identifiable, making this a flow-driven move that could reverse if buyers step back. The Danaher headline is tangentially relevant to the sector but not directly supportive. On balance, the absence of a strong fade catalyst and ample time remaining keep this in continuation territory, but only modestly above the threshold.

  100. !Nov 3, 10:20 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 2.05% today with no single attributable headline driving the move, suggesting underlying institutional flow rather than a headline-driven pop that might fade. The move is meaningful in magnitude but sits at the lower end of the 2-5% range, indicating moderate rather than strong conviction. With 325 minutes remaining (~5.4 hours), there is ample time for continuation if momentum holds, which is a positive factor. However, several headwinds temper enthusiasm: (1) macro context shows DFF running 2.2σ above trend, which is a tightening signal that pressures growth/life-sciences names like TMO; (2) one headline flags TMO as among '3 S&P 500 stocks we find risky,' which could weigh on sentiment or attract short interest; (3) no clearly bullish catalyst is identifiable, making this a flow-driven move that could reverse if buyers step back. The Danaher headline is tangentially relevant to the sector but not directly supportive. On balance, the absence of a strong fade catalyst and ample time remaining keep this in continuation territory, but only modestly above the threshold.

  101. ?Nov 2, 12:47 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.82% today, which is a meaningful move but sits just below the 2% threshold where conviction flows typically carry stronger continuation signals. Headlines are entirely generic market research reports and a retrospective piece — no catalyst either way, and no company-specific news to explain the move or reinforce it. Macro context (elevated mortgage rates) is sector-irrelevant for TMO (life sciences tools). With 179 minutes remaining there is ample time for continuation, but without a clear catalyst driving the selloff and no macro headwind specific to healthcare/life sciences, this looks more like broad market pressure or institutional rebalancing that may stabilize or fade intraday. The absence of a clear fundamental driver reduces conviction for continuation. Given the borderline setup and no strong reason to expect sustained selling pressure into the close, probability sits just below the 0.5 trigger threshold — not a trade.

  102. !Nov 2, 12:47 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.82% today, which is a meaningful move but sits just below the 2% threshold where conviction flows typically carry stronger continuation signals. Headlines are entirely generic market research reports and a retrospective piece — no catalyst either way, and no company-specific news to explain the move or reinforce it. Macro context (elevated mortgage rates) is sector-irrelevant for TMO (life sciences tools). With 179 minutes remaining there is ample time for continuation, but without a clear catalyst driving the selloff and no macro headwind specific to healthcare/life sciences, this looks more like broad market pressure or institutional rebalancing that may stabilize or fade intraday. The absence of a clear fundamental driver reduces conviction for continuation. Given the borderline setup and no strong reason to expect sustained selling pressure into the close, probability sits just below the 0.5 trigger threshold — not a trade.

  103. ?Nov 2, 9:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.65% today, which is a moderate but not extreme intraday move. There is no company-specific news driving the decline — the headlines are generic/retrospective and provide no directional catalyst. The macro context (elevated mortgage rates at 2.3σ above trend) is not directly relevant to TMO as a life sciences/instrumentation company. With 360 minutes remaining (essentially the full trading day still ahead), there is ample time for either continuation or reversal. The absence of a clear catalyst makes this a pure momentum read: the move is real but not large enough to confidently signal sustained institutional selling. No reversal pattern is evident from the data provided. Given the bounded risk profile of the system (tight -1.5% stop, +3% target), the default lean per the framework is to take the trade at the 0.5 threshold. Assigning exactly 0.5 — momentum is present but conviction is limited without a fundamental driver.

  104. !Nov 2, 9:45 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.65% today, which is a moderate but not extreme intraday move. There is no company-specific news driving the decline — the headlines are generic/retrospective and provide no directional catalyst. The macro context (elevated mortgage rates at 2.3σ above trend) is not directly relevant to TMO as a life sciences/instrumentation company. With 360 minutes remaining (essentially the full trading day still ahead), there is ample time for either continuation or reversal. The absence of a clear catalyst makes this a pure momentum read: the move is real but not large enough to confidently signal sustained institutional selling. No reversal pattern is evident from the data provided. Given the bounded risk profile of the system (tight -1.5% stop, +3% target), the default lean per the framework is to take the trade at the 0.5 threshold. Assigning exactly 0.5 — momentum is present but conviction is limited without a fundamental driver.

  105. ✓Oct 28, 10:16 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    TMO is up 2.34% intraday, a meaningful move indicating real buying conviction. A 'Breakout Watch' headline with 4 bullish catalysts cited for a top-rated medical stock provides some narrative support for continuation. With 330 minutes remaining (essentially the full afternoon session still ahead), there is ample time for momentum to extend toward the +3% target. The macro backdrop (T10Y2Y at 1.7σ below trend, favoring defensives) is modestly supportive for a high-quality large-cap healthcare name like TMO, which tends to attract defensive rotation in flattening curve environments. No reversal signals or fade patterns are noted. The absence of a major news catalyst is not disqualifying given the size of the move already printed. Overall, this reads as ordinary momentum with mild fundamental and macro tailwinds — probability sits in the 0.60-0.65 range.

  106. ▢Oct 27, 8:00 PMjournal

    Agent 7 — Day Trader opened long 4 @ $709.21

  107. ▣Oct 27, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 4 @ $706.50 (-$10.84)

    EOD forced close — day trader never carries overnight

  108. ?Oct 20, 3:06 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 1.72% today, a meaningful move suggesting real buying conviction. A bullish headline ('Why Thermo Fisher Could Beat Earnings Estimates Again') provides a fundamental catalyst that can sustain interest into the close. However, several factors cap the probability: (1) Only 40 minutes remain until the forced close cutoff, leaving limited runway for further gains toward the +3% target. (2) The macro environment is a mild headwind — 2-year yields are running 2.0σ above trend at 4.74%, which pressures long-duration growth/life-science names like TMO on valuation grounds. (3) The move at 1.72% is meaningful but not extreme, so there's no clear blow-off or exhaustion signal to fade, but also no overwhelming momentum to chase. (4) No volume data is available to confirm institutional follow-through. On balance, the earnings-beat narrative and existing momentum give a slight edge to continuation, but the short time window and rate headwind keep conviction modest. Setting probability just above the action threshold.

  109. !Oct 20, 3:06 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 1.72% today, a meaningful move suggesting real buying conviction. A bullish headline ('Why Thermo Fisher Could Beat Earnings Estimates Again') provides a fundamental catalyst that can sustain interest into the close. However, several factors cap the probability: (1) Only 40 minutes remain until the forced close cutoff, leaving limited runway for further gains toward the +3% target. (2) The macro environment is a mild headwind — 2-year yields are running 2.0σ above trend at 4.74%, which pressures long-duration growth/life-science names like TMO on valuation grounds. (3) The move at 1.72% is meaningful but not extreme, so there's no clear blow-off or exhaustion signal to fade, but also no overwhelming momentum to chase. (4) No volume data is available to confirm institutional follow-through. On balance, the earnings-beat narrative and existing momentum give a slight edge to continuation, but the short time window and rate headwind keep conviction modest. Setting probability just above the action threshold.

  110. ?Oct 19, 1:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.60% today, which is a moderate but not dramatic intraday move. There are no recent headlines to attribute the move to, making it harder to assess whether there is sustained conviction behind the selling. The macro context (elevated mortgage rates at 7.4%, 3.3σ above trend) is sector-specific to homebuilders, REITs, and banks — not directly relevant to TMO (life sciences tools/instrumentation), so there is no macro tailwind or headwind specific to this ticker. With 120 minutes remaining, there is ample time for the move to extend, but also for mean reversion. The move at -1.60% is below the 2-5% threshold where we'd assign strong continuation conviction. No reversal signals are explicitly present, and no volume anomalies are noted. With no compelling reason to expect a fade but also no strong continuation catalyst, this is a borderline read. Per the system's instructions, borderline reads resolve in favor of taking the trade given bounded risk and the 0.5 cutoff, so probability is set at exactly 0.5 — the minimum threshold for a position.

  111. !Oct 19, 1:45 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.60% today, which is a moderate but not dramatic intraday move. There are no recent headlines to attribute the move to, making it harder to assess whether there is sustained conviction behind the selling. The macro context (elevated mortgage rates at 7.4%, 3.3σ above trend) is sector-specific to homebuilders, REITs, and banks — not directly relevant to TMO (life sciences tools/instrumentation), so there is no macro tailwind or headwind specific to this ticker. With 120 minutes remaining, there is ample time for the move to extend, but also for mean reversion. The move at -1.60% is below the 2-5% threshold where we'd assign strong continuation conviction. No reversal signals are explicitly present, and no volume anomalies are noted. With no compelling reason to expect a fade but also no strong continuation catalyst, this is a borderline read. Per the system's instructions, borderline reads resolve in favor of taking the trade given bounded risk and the 0.5 cutoff, so probability is set at exactly 0.5 — the minimum threshold for a position.

  112. ?Oct 15, 3:26 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 3.93% today, a meaningful move with clear institutional conviction behind it. However, with only 20 minutes remaining until the forced close, the time window is extremely compressed — even a well-supported setup has limited room to add another +3% before 3:45 PM ET. The macro context (30-year mortgage rate at 7.4%, 3.3σ above trend) is not directly relevant to TMO's business (life sciences tools/diagnostics), so it neither supports nor undermines the move. No headlines are present to explain the catalyst, which is not disqualifying per se, but the combination of (1) a move already extended ~4% without an identifiable headline, (2) late-session timing where profit-taking and position flattening by other intraday traders is likely, and (3) only 20 minutes remaining creating very little runway to reach the +3% target before forced close — collectively pushes the probability below the 0.5 threshold. The risk here is not the direction (which looks legitimately bullish today) but the timing: the expected value of entering a position this late in the session on an already-extended move, with a fixed +3% target that requires the stock to reach ~$720.65, is negative. Fading probability due to time exhaustion, not directional doubt.

  113. !Oct 15, 3:26 PMsignalseverity 0.04

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 3.93% today, a meaningful move with clear institutional conviction behind it. However, with only 20 minutes remaining until the forced close, the time window is extremely compressed — even a well-supported setup has limited room to add another +3% before 3:45 PM ET. The macro context (30-year mortgage rate at 7.4%, 3.3σ above trend) is not directly relevant to TMO's business (life sciences tools/diagnostics), so it neither supports nor undermines the move. No headlines are present to explain the catalyst, which is not disqualifying per se, but the combination of (1) a move already extended ~4% without an identifiable headline, (2) late-session timing where profit-taking and position flattening by other intraday traders is likely, and (3) only 20 minutes remaining creating very little runway to reach the +3% target before forced close — collectively pushes the probability below the 0.5 threshold. The risk here is not the direction (which looks legitimately bullish today) but the timing: the expected value of entering a position this late in the session on an already-extended move, with a fixed +3% target that requires the stock to reach ~$720.65, is negative. Fading probability due to time exhaustion, not directional doubt.

  114. ?Oct 14, 12:45 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 1.65% today, a moderate but meaningful intraday move. The primary catalyst appears to be pre-earnings positioning — a headline notes TMO reports next week with Wall Street expecting earnings growth, which can create multi-day accumulation flow as institutions build positions ahead of the print. This is a mild positive for continuation. However, the macro context is a mild headwind: 5Y5Y forward inflation running 1.5σ above trend implies elevated rate expectations, which historically pressures high-multiple healthcare/instruments names like TMO. The move itself is below the 2-5% high-conviction threshold, so momentum evidence is moderate rather than strong. With 180 minutes remaining there is ample time for continuation or fade. No reversal pattern is evident from the data provided. Balancing pre-earnings drift tailwind against the rate-sensitive macro overhang and moderate move magnitude, this sits in the low-probability continuation zone — enough to lean long given bounded risk but without high conviction.

  115. !Oct 14, 12:45 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 1.65% today, a moderate but meaningful intraday move. The primary catalyst appears to be pre-earnings positioning — a headline notes TMO reports next week with Wall Street expecting earnings growth, which can create multi-day accumulation flow as institutions build positions ahead of the print. This is a mild positive for continuation. However, the macro context is a mild headwind: 5Y5Y forward inflation running 1.5σ above trend implies elevated rate expectations, which historically pressures high-multiple healthcare/instruments names like TMO. The move itself is below the 2-5% high-conviction threshold, so momentum evidence is moderate rather than strong. With 180 minutes remaining there is ample time for continuation or fade. No reversal pattern is evident from the data provided. Balancing pre-earnings drift tailwind against the rate-sensitive macro overhang and moderate move magnitude, this sits in the low-probability continuation zone — enough to lean long given bounded risk but without high conviction.

  116. ?Oct 14, 10:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 1.65% today — a moderate but meaningful intraday move suggesting real buying flow. The move is below the 2-5% threshold where momentum becomes strongly self-reinforcing, so it reads as steady accumulation rather than a high-conviction breakout. Headlines are generic market research reports mentioning TMO as a sector participant — no company-specific catalyst driving the move, but absence of news doesn't disqualify continuation. Macro context is mildly unfavorable: the 5Y5Y forward inflation rate is running 1.5σ above trend, which suggests elevated real rate expectations that can pressure growth/quality names like TMO. However, TMO's defensive characteristics in life sciences tools partially buffer rate sensitivity. With 310 minutes remaining (well over 5 hours), there is ample time for the move to extend or consolidate. No reversal signals are evident — the stock is not fading off highs based on available data. Net assessment: modest upward continuation bias with no strong catalyst to reverse, balanced against a slightly adverse macro rate backdrop. Probability sits just above the neutral threshold.

  117. !Oct 14, 10:35 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 1.65% today — a moderate but meaningful intraday move suggesting real buying flow. The move is below the 2-5% threshold where momentum becomes strongly self-reinforcing, so it reads as steady accumulation rather than a high-conviction breakout. Headlines are generic market research reports mentioning TMO as a sector participant — no company-specific catalyst driving the move, but absence of news doesn't disqualify continuation. Macro context is mildly unfavorable: the 5Y5Y forward inflation rate is running 1.5σ above trend, which suggests elevated real rate expectations that can pressure growth/quality names like TMO. However, TMO's defensive characteristics in life sciences tools partially buffer rate sensitivity. With 310 minutes remaining (well over 5 hours), there is ample time for the move to extend or consolidate. No reversal signals are evident — the stock is not fading off highs based on available data. Net assessment: modest upward continuation bias with no strong catalyst to reverse, balanced against a slightly adverse macro rate backdrop. Probability sits just above the neutral threshold.

  118. ?Oct 8, 1:05 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 2.67% today, a meaningful move indicating real selling pressure. Headlines are vague ('back in spotlight', gap list inclusion) and don't provide a clear bullish catalyst to reverse the move. Macro context around elevated mortgage rates (7.4%, 3.8σ above trend) is not directly sector-relevant to life sciences/instruments, so it neither supports nor undermines the move. With 160 minutes remaining there is ample time for continuation, but the absence of a clear fundamental driver for the decline (suggesting possible sector rotation or broader market drag rather than company-specific news) introduces some uncertainty about follow-through. No clear reversal signal is evident. Overall, momentum leans modestly toward continuation of the downside move into the close, but conviction is limited — rating this a borderline continuation setup.

  119. !Oct 8, 1:05 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 2.67% today, a meaningful move indicating real selling pressure. Headlines are vague ('back in spotlight', gap list inclusion) and don't provide a clear bullish catalyst to reverse the move. Macro context around elevated mortgage rates (7.4%, 3.8σ above trend) is not directly sector-relevant to life sciences/instruments, so it neither supports nor undermines the move. With 160 minutes remaining there is ample time for continuation, but the absence of a clear fundamental driver for the decline (suggesting possible sector rotation or broader market drag rather than company-specific news) introduces some uncertainty about follow-through. No clear reversal signal is evident. Overall, momentum leans modestly toward continuation of the downside move into the close, but conviction is limited — rating this a borderline continuation setup.

  120. ?Oct 8, 10:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 3.75% today, a meaningful move indicating real selling pressure. Headlines are neutral market-research pieces with no specific catalysts to arrest the decline. The macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend, which is a headwind for rate-sensitive growth/life-science names like TMO (high-multiple, capex-intensive). With 315 minutes remaining (essentially full afternoon session), there is ample time for the move to extend. However, a 3.75% drop is already significant and profit-taking by shorts or dip-buyers could slow momentum. No clear reversal signal is present, and no positive catalyst is visible in recent headlines. The setup is ordinary momentum continuation — modest probability assigned for downside continuation given macro headwind alignment and absence of a reversal trigger, but not high-conviction given the magnitude already achieved and potential for mean reversion in a large-cap name.

  121. !Oct 8, 10:30 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 3.75% today, a meaningful move indicating real selling pressure. Headlines are neutral market-research pieces with no specific catalysts to arrest the decline. The macro context shows 5-year forward inflation expectations elevated at 1.8σ above trend, which is a headwind for rate-sensitive growth/life-science names like TMO (high-multiple, capex-intensive). With 315 minutes remaining (essentially full afternoon session), there is ample time for the move to extend. However, a 3.75% drop is already significant and profit-taking by shorts or dip-buyers could slow momentum. No clear reversal signal is present, and no positive catalyst is visible in recent headlines. The setup is ordinary momentum continuation — modest probability assigned for downside continuation given macro headwind alignment and absence of a reversal trigger, but not high-conviction given the magnitude already achieved and potential for mean reversion in a large-cap name.

  122. ?Oct 6, 12:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 2.35% with 190 minutes remaining — a meaningful move with ample time to extend. No headlines are present, but absence of news doesn't negate the real selling flow already observed. The macro context shows 5-year forward inflation expectations (T5YIFR) running 2.0σ above trend, which pressures rate-sensitive and high-multiple sectors. TMO, as a large-cap life sciences/instrumentation name with a premium valuation, is sensitive to discount rate headwinds from elevated inflation expectations. This macro backdrop provides a plausible tailwind for continued selling pressure rather than a reversal. However, several factors limit conviction: (1) no identifiable catalyst or news to sustain seller urgency into the close, (2) a 2.35% decline is already a notable move and some mean reversion is possible intraday, (3) the macro factor is a slow-moving backdrop rather than a fresh acute catalyst. On balance, the path of least resistance favors modest continuation given the macro rate environment and real intraday flow, but this is a borderline setup — probability set just above the action threshold.

  123. !Oct 6, 12:35 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 2.35% with 190 minutes remaining — a meaningful move with ample time to extend. No headlines are present, but absence of news doesn't negate the real selling flow already observed. The macro context shows 5-year forward inflation expectations (T5YIFR) running 2.0σ above trend, which pressures rate-sensitive and high-multiple sectors. TMO, as a large-cap life sciences/instrumentation name with a premium valuation, is sensitive to discount rate headwinds from elevated inflation expectations. This macro backdrop provides a plausible tailwind for continued selling pressure rather than a reversal. However, several factors limit conviction: (1) no identifiable catalyst or news to sustain seller urgency into the close, (2) a 2.35% decline is already a notable move and some mean reversion is possible intraday, (3) the macro factor is a slow-moving backdrop rather than a fresh acute catalyst. On balance, the path of least resistance favors modest continuation given the macro rate environment and real intraday flow, but this is a borderline setup — probability set just above the action threshold.

  124. ✓Oct 6, 9:35 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    TMO is up 2.01% today on a combination of positive catalysts: a new contract win with Quantum BioPharma for a Phase 2 MS trial, showcase presence at CPHI Milan 2026, and general sector visibility. The headlines are modestly positive but not transformative — the Quantum BioPharma deal is relatively small in scale for a company of TMO's size. The macro context is a mild headwind: the 5Y5Y inflation forward (T5YIFR) is running 2.0σ above trend, which can pressure rate-sensitive and high-multiple names like TMO. However, the move so far is real and reflects genuine buying interest. With 370 minutes remaining (well before the 3:45 PM cutoff), there is ample time for continuation. No reversal pattern is evident — the move appears directional rather than a spike-and-fade. The macro headwind is modest and not sector-specific enough to override the momentum signal. On balance, ordinary momentum continuation is the base case with no strong reason to expect a fade, yielding a modest positive probability.

  125. ▢Oct 5, 8:00 PMjournal

    Agent 7 — Day Trader opened long 4 @ $690.34

  126. ▣Oct 5, 8:00 PMjournalstop

    Agent 7 — Day Trader closed long 4 @ $679.41 (-$43.72)

    Long stop: close $679.41 ≤ stop $679.98

  127. ?Sep 24, 10:45 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 1.76% today, a moderate but meaningful intraday move suggesting real buying interest. News flow is modestly constructive — product launches (Gibco CHO K1 panel, new media panel for biologics development) and positive sector mentions across multiple market reports indicate underlying fundamental support, though none of these headlines are high-impact catalysts on their own. The macro context is a mild headwind: the 5-year forward inflation rate printing 2.0σ above trend suggests elevated rate sensitivity, which can weigh on growth-oriented healthcare/life science tools names like TMO at the margin. However, with 300 minutes remaining (a full session's worth of time effectively), there is ample runway for the move to extend. The move magnitude (1.76%) is real but not exhausted — it hasn't stretched into the 3-5% range where fade risk escalates sharply. No reversal pattern or volume concern is indicated. On balance, momentum and time remaining support a mild continuation lean, offset slightly by the macro rate context and absence of a single strong catalyst. Assigning a modest continuation probability just above the threshold.

  128. !Sep 24, 10:45 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 1.76% today, a moderate but meaningful intraday move suggesting real buying interest. News flow is modestly constructive — product launches (Gibco CHO K1 panel, new media panel for biologics development) and positive sector mentions across multiple market reports indicate underlying fundamental support, though none of these headlines are high-impact catalysts on their own. The macro context is a mild headwind: the 5-year forward inflation rate printing 2.0σ above trend suggests elevated rate sensitivity, which can weigh on growth-oriented healthcare/life science tools names like TMO at the margin. However, with 300 minutes remaining (a full session's worth of time effectively), there is ample runway for the move to extend. The move magnitude (1.76%) is real but not exhausted — it hasn't stretched into the 3-5% range where fade risk escalates sharply. No reversal pattern or volume concern is indicated. On balance, momentum and time remaining support a mild continuation lean, offset slightly by the macro rate context and absence of a single strong catalyst. Assigning a modest continuation probability just above the threshold.

  129. ✓Sep 17, 6:21 PMdecisionacted

    Agent 20 — SIR Price/Volume — buy

    [cluster_break_up] From 2026-08-24 through 2026-09-14, TMO's PV path coiled in a tight price cluster between roughly $600 and $634 on consistently subdued volume (1.0M–2.0M shares, well at or below the 1.8M ADV), tracing a classic low-energy consolidation zone in 2-D space. The breakout began on 2026-09-15 when price surged to $641.39 on 3.0M volume (+67% above ADV), then extended to $648.43 on 2.9M (2026-09-16), and today (2026-09-17) accelerated to $658.32 on 4.2M — a volume z-score of +4.12 — confirming that fresh, outsized demand is absorbing the float well above the cluster ceiling. Critically, this is a three-session, multi-dot confirmation of the break (not a single-bar event), with each successive close printing a higher price and volume remaining firmly elevated, which is precisely the up-and-right path extension the SIR framework requires to validate a cluster_break_up signal. Risks: A reversal back below the former cluster ceiling (~$633–$634) on elevated volume would signal a false breakout and invalidate the bullish read entirely. Additionally, the yield-curve context (T10Y2Y at 0.27, 2.4σ below trend) suggests macro fragility; any sudden risk-off rotation hitting the broader Health Care sector could undercut demand before the breakout consolidates.

  130. ?Sep 15, 10:21 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 2.13% intraday with 325 minutes remaining — ample time for continuation. The move is meaningful and suggests real institutional flow, though at 2.13% it sits at the lower end of the 'strong conviction' range. No headlines are present to explain the move, which is not disqualifying but limits our ability to assess whether a catalyst is durable or already fully priced. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.8σ above trend, which is modestly unfavorable for rate-sensitive sectors broadly; however, TMO as a life sciences / analytical instruments company is not deeply rate-sensitive in the same way as REITs or utilities — this macro headwind is mild and indirect. With no reversal signals noted, no thin-volume flags, and substantial time remaining, the base case favors gentle continuation into the close driven by momentum. Probability stays in the moderate range rather than elevated because: (1) no clear catalyst to sustain conviction buying, (2) slightly elevated inflation expectations could weigh on growth-oriented names at the margin, and (3) the move, while real, is not large enough on its own to signal an unusually aggressive accumulation event.

  131. !Sep 15, 10:21 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 2.13% intraday with 325 minutes remaining — ample time for continuation. The move is meaningful and suggests real institutional flow, though at 2.13% it sits at the lower end of the 'strong conviction' range. No headlines are present to explain the move, which is not disqualifying but limits our ability to assess whether a catalyst is durable or already fully priced. The macro context shows 5-year forward inflation expectations (T5YIFR) running 1.8σ above trend, which is modestly unfavorable for rate-sensitive sectors broadly; however, TMO as a life sciences / analytical instruments company is not deeply rate-sensitive in the same way as REITs or utilities — this macro headwind is mild and indirect. With no reversal signals noted, no thin-volume flags, and substantial time remaining, the base case favors gentle continuation into the close driven by momentum. Probability stays in the moderate range rather than elevated because: (1) no clear catalyst to sustain conviction buying, (2) slightly elevated inflation expectations could weigh on growth-oriented names at the margin, and (3) the move, while real, is not large enough on its own to signal an unusually aggressive accumulation event.

  132. ?Sep 4, 9:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.52% today, a moderate but not outsized move. There are no recent headlines to explain the decline, suggesting this is either broad market pressure or quiet institutional flow. The macro context shows the 5-year forward inflation rate (T5YIFR) printing 1.7σ above its 24-month trend, which signals elevated rate-sensitivity across sectors. TMO, as a large-cap life sciences instrument/services company, has some rate sensitivity through its valuation multiple, which could contribute to mild selling pressure in a rising-rate-expectations environment. However, at -1.52%, the move is not large enough to signal exceptional conviction, and the absence of news cuts both ways. With 350 minutes remaining (well before the cutoff), there is ample time for continuation. The elevated inflation expectations backdrop provides a mild but real fundamental reason for the selling to persist rather than reverse. No reversal signals are evident. Overall, this is a borderline continuation setup — the macro headwind is modest but directionally consistent with the move, supporting a neutral-to-slight continuation probability. Assigning 0.5 as the move is real but not compelling enough to push higher without stronger volume or news confirmation.

  133. !Sep 4, 9:55 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.52% today, a moderate but not outsized move. There are no recent headlines to explain the decline, suggesting this is either broad market pressure or quiet institutional flow. The macro context shows the 5-year forward inflation rate (T5YIFR) printing 1.7σ above its 24-month trend, which signals elevated rate-sensitivity across sectors. TMO, as a large-cap life sciences instrument/services company, has some rate sensitivity through its valuation multiple, which could contribute to mild selling pressure in a rising-rate-expectations environment. However, at -1.52%, the move is not large enough to signal exceptional conviction, and the absence of news cuts both ways. With 350 minutes remaining (well before the cutoff), there is ample time for continuation. The elevated inflation expectations backdrop provides a mild but real fundamental reason for the selling to persist rather than reverse. No reversal signals are evident. Overall, this is a borderline continuation setup — the macro headwind is modest but directionally consistent with the move, supporting a neutral-to-slight continuation probability. Assigning 0.5 as the move is real but not compelling enough to push higher without stronger volume or news confirmation.

  134. ?Sep 1, 11:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 2.00% intraday with 260 minutes remaining — substantial time left for continuation. No news headlines are present, but the move itself represents meaningful selling flow with conviction. TMO is a high-quality large-cap life sciences/instrumentation name that trades somewhat like long-duration growth (elevated P/E, sensitive to rate environment). The macro context shows 2-year yields running 2.0σ above the 24-month trend at 4.34%, which creates a headwind for rate-sensitive growth equities including TMO — this is a mild tailwind for continued downside. However, TMO is not a pure-play tech name and has defensive characteristics (recurring revenue, pharma/biopharma end markets) that could attract buyers at these levels. The absence of specific catalysts (earnings, guidance, deal news) means this move is likely macro/sector-driven or fund-flow driven, which can persist but also fades when sellers exhaust. With ample time remaining and rate pressure as a backdrop, lean modestly toward continuation but without strong conviction — no clear reversal signal, no volume anomaly data suggesting exhaustion. Probability set at 0.52 reflecting ordinary momentum with a mild macro tailwind for the bearish thesis.

  135. !Sep 1, 11:25 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 2.00% intraday with 260 minutes remaining — substantial time left for continuation. No news headlines are present, but the move itself represents meaningful selling flow with conviction. TMO is a high-quality large-cap life sciences/instrumentation name that trades somewhat like long-duration growth (elevated P/E, sensitive to rate environment). The macro context shows 2-year yields running 2.0σ above the 24-month trend at 4.34%, which creates a headwind for rate-sensitive growth equities including TMO — this is a mild tailwind for continued downside. However, TMO is not a pure-play tech name and has defensive characteristics (recurring revenue, pharma/biopharma end markets) that could attract buyers at these levels. The absence of specific catalysts (earnings, guidance, deal news) means this move is likely macro/sector-driven or fund-flow driven, which can persist but also fades when sellers exhaust. With ample time remaining and rate pressure as a backdrop, lean modestly toward continuation but without strong conviction — no clear reversal signal, no volume anomaly data suggesting exhaustion. Probability set at 0.52 reflecting ordinary momentum with a mild macro tailwind for the bearish thesis.

  136. ?Aug 28, 1:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down -1.77% today, which is a meaningful move but sits just below the 2% threshold where conviction signals become stronger. With 155 minutes remaining, there is ample time for continuation if selling pressure persists. No specific news catalyst is identifiable, but large-cap healthcare/life sciences names like TMO can see institutional flow-driven moves that persist intraday without headline attribution. The macro context (elevated mortgage rates at 1.8σ above trend) is broadly risk-cautious and slightly negative for equities generally, though TMO is not directly a rate-sensitive sector play — this is a weak tailwind for continuation of the down move at best. Absence of a reversal catalyst or bullish headline keeps the base case tilted toward momentum continuation. However, the move is not yet large enough to signal strong institutional conviction, and without volume data confirming the selloff, the probability stays near the lower end of the continuation band. Assigning a modest 0.51 — slight lean toward continued downside into the close, but no strong setup.

  137. !Aug 28, 1:10 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down -1.77% today, which is a meaningful move but sits just below the 2% threshold where conviction signals become stronger. With 155 minutes remaining, there is ample time for continuation if selling pressure persists. No specific news catalyst is identifiable, but large-cap healthcare/life sciences names like TMO can see institutional flow-driven moves that persist intraday without headline attribution. The macro context (elevated mortgage rates at 1.8σ above trend) is broadly risk-cautious and slightly negative for equities generally, though TMO is not directly a rate-sensitive sector play — this is a weak tailwind for continuation of the down move at best. Absence of a reversal catalyst or bullish headline keeps the base case tilted toward momentum continuation. However, the move is not yet large enough to signal strong institutional conviction, and without volume data confirming the selloff, the probability stays near the lower end of the continuation band. Assigning a modest 0.51 — slight lean toward continued downside into the close, but no strong setup.

  138. ?Jul 31, 10:30 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.80% today, a moderate but not dramatic move. There are no headlines to explain the move, which means it's likely driven by broader market flows or sector rotation rather than stock-specific news. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to TMO as a life sciences/analytical instruments company. With 315 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to continue, but also ample time for mean reversion. The move is below the 2% threshold that would suggest strong institutional conviction. No reversal signals are evident, and absence of news doesn't disqualify continuation. Given the bounded risk structure (1.5% stop, 3% target, forced flatten), the marginal lean is toward continuation of the downward drift, but confidence is low — this is a borderline read with no strong catalysts in either direction.

  139. !Jul 31, 10:30 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.80% today, a moderate but not dramatic move. There are no headlines to explain the move, which means it's likely driven by broader market flows or sector rotation rather than stock-specific news. The macro context (elevated mortgage rates at 1.9σ above trend) is not directly relevant to TMO as a life sciences/analytical instruments company. With 315 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to continue, but also ample time for mean reversion. The move is below the 2% threshold that would suggest strong institutional conviction. No reversal signals are evident, and absence of news doesn't disqualify continuation. Given the bounded risk structure (1.5% stop, 3% target, forced flatten), the marginal lean is toward continuation of the downward drift, but confidence is low — this is a borderline read with no strong catalysts in either direction.

  140. ?Jul 24, 10:05 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.62% with 340 minutes remaining — a moderate move with substantial time left in the session. The move is meaningful but not yet at the 2-5% range that would signal strong conviction flow. No headlines are present to attribute the move to a catalyst, which is neutral per guidance. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly supportive of defensive sectors like healthcare/life sciences tools where TMO operates — a flattening curve can dampen risk appetite and favor rotation pressure against growth-sensitive names, but TMO is not a pure cyclical so this is a weak tailwind for continuation of the downside. With no clear reversal signal and ample time remaining, momentum bias leans toward continuation. Probability is kept modest at 0.52 given the absence of a strong catalyst, moderate move size, and the mild macro read that doesn't strongly reinforce further selling pressure.

  141. !Jul 24, 10:05 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.62% with 340 minutes remaining — a moderate move with substantial time left in the session. The move is meaningful but not yet at the 2-5% range that would signal strong conviction flow. No headlines are present to attribute the move to a catalyst, which is neutral per guidance. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly supportive of defensive sectors like healthcare/life sciences tools where TMO operates — a flattening curve can dampen risk appetite and favor rotation pressure against growth-sensitive names, but TMO is not a pure cyclical so this is a weak tailwind for continuation of the downside. With no clear reversal signal and ample time remaining, momentum bias leans toward continuation. Probability is kept modest at 0.52 given the absence of a strong catalyst, moderate move size, and the mild macro read that doesn't strongly reinforce further selling pressure.

  142. ?Jul 23, 6:03 PMdecisionconsidered

    Agent 20 — SIR Price/Volume — buy

    [not executed — reserve_floor_or_cash] [cluster_break_up] From 2026-07-09 through 2026-07-22, TMO traced a tight consolidation cluster in the $510–$543 range on notably subdued volume (1.2M–2.1M/day, well below the 20-day ADV of 2.1M), with up-days like 2026-07-10 ($527.05, 1.2M) and 2026-07-13 ($528.51, 1.2M) printing some of the lightest volume in the entire window — a classic low-volume price shelf. On 2026-07-23, TMO exploded out of that cluster to $572.09 (+8.67%) on 5.2M shares — a volume z-score of 3.79 and more than 2.5× the trailing ADV — unambiguously breaking above the prior range on materially expanding demand, the textbook SIR cluster_break_up signature. The path through 2-D space shows the dot leaping sharply up-and-right, departing the dense cluster decisively, which under SIR's framework signals fresh institutional demand absorbing the float at a new price level. Risks: This is a single-bar event — SIR's methodology demands multi-session confirmation, and if the next 1–3 sessions see price fall back below ~$543 (the top of the prior cluster) on elevated volume, the breakout would be classified as a failed break or exhaustion/bull trap rather than genuine accumulation. Additionally, the macro backdrop (T10Y2Y at 0.36, 1.8σ below trend) suggests a flattening/defensive yield environment that could pressure growth-oriented Health Care names if risk appetite deteriorates, limiting follow-through.

  143. ?Jul 17, 12:25 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.66% today, a meaningful but not extreme move. There are no news catalysts to explain the selloff, which cuts both ways — no fresh negative catalyst to sustain it, but also no obvious reason for a snap reversal. The macro backdrop is modestly supportive for long-duration sensitive sectors (T10YIE at 1.6σ below trend implies lower real yields, which is a mild tailwind for growth/healthcare names like TMO), slightly working against continuation of the downside move. However, with 200 minutes remaining there is ample time for the move to extend if institutional selling pressure persists. The absence of news, moderate move size, and slightly supportive macro context balance out — no strong reason to expect either continuation or reversal. Assigning the minimum threshold probability, leaning barely into continuation given the base rate that intraday moves more often continue than fully reverse within session.

  144. !Jul 17, 12:25 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is down 1.66% today, a meaningful but not extreme move. There are no news catalysts to explain the selloff, which cuts both ways — no fresh negative catalyst to sustain it, but also no obvious reason for a snap reversal. The macro backdrop is modestly supportive for long-duration sensitive sectors (T10YIE at 1.6σ below trend implies lower real yields, which is a mild tailwind for growth/healthcare names like TMO), slightly working against continuation of the downside move. However, with 200 minutes remaining there is ample time for the move to extend if institutional selling pressure persists. The absence of news, moderate move size, and slightly supportive macro context balance out — no strong reason to expect either continuation or reversal. Assigning the minimum threshold probability, leaning barely into continuation given the base rate that intraday moves more often continue than fully reverse within session.

  145. ▣Jul 14, 8:00 PMjournaltarget

    Agent 4 — Dip Buyer (Frozen) closed long 2 @ $535.51 (+$123.26)

    Target hit: close $535.51 ≥ target $529.99

  146. ?Jul 9, 3:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 2.09% today with only 25 minutes remaining until the forced close. The move is meaningful and reflects real institutional flow, but the combination of very limited time remaining and a flat/slightly bearish macro backdrop (T10Y2Y at 2.1σ below trend, suggesting defensives could be reactive but in a bear-flattening context which isn't necessarily bullish for a large-cap healthcare/instruments name like TMO) gives limited runway. With only 25 minutes left, even a genuine continuation signal has little room to develop before EOD flatten. No headlines to support or refute the move. The risk here is that the 2% move may already represent the bulk of today's flow, and late-session profit-taking or mean reversion in the final 25 minutes is a real possibility. Probability falls below the 0.5 threshold — this does not trigger a position.

  147. !Jul 9, 3:20 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 2.09% today with only 25 minutes remaining until the forced close. The move is meaningful and reflects real institutional flow, but the combination of very limited time remaining and a flat/slightly bearish macro backdrop (T10Y2Y at 2.1σ below trend, suggesting defensives could be reactive but in a bear-flattening context which isn't necessarily bullish for a large-cap healthcare/instruments name like TMO) gives limited runway. With only 25 minutes left, even a genuine continuation signal has little room to develop before EOD flatten. No headlines to support or refute the move. The risk here is that the 2% move may already represent the bulk of today's flow, and late-session profit-taking or mean reversion in the final 25 minutes is a real possibility. Probability falls below the 0.5 threshold — this does not trigger a position.

  148. ?Jul 9, 2:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 2.14% today with no attributable headline, suggesting institutional flow or broad sector rotation into large-cap life sciences/defensives. The macro context (T10Y2Y at 2.1σ below trend, bear-flattening signal) actually provides a mild tailwind for defensive/healthcare names like TMO as yield curve compression tends to drive rotation away from banks and cyclicals toward quality defensives. No reversal signals or fade patterns are noted. However, with 85 minutes remaining, there is moderate but not ample time left, and the absence of a catalyst means the move could simply consolidate rather than extend. The 2.14% move is meaningful but sits at the lower bound of the 2-5% 'high conviction' range. On balance, momentum bias and defensive sector support edge this into continuation territory, but without a strong catalyst or clear sustained trend data, probability is modest above the 0.5 threshold.

  149. !Jul 9, 2:20 PMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    TMO is up 2.14% today with no attributable headline, suggesting institutional flow or broad sector rotation into large-cap life sciences/defensives. The macro context (T10Y2Y at 2.1σ below trend, bear-flattening signal) actually provides a mild tailwind for defensive/healthcare names like TMO as yield curve compression tends to drive rotation away from banks and cyclicals toward quality defensives. No reversal signals or fade patterns are noted. However, with 85 minutes remaining, there is moderate but not ample time left, and the absence of a catalyst means the move could simply consolidate rather than extend. The 2.14% move is meaningful but sits at the lower bound of the 2-5% 'high conviction' range. On balance, momentum bias and defensive sector support edge this into continuation territory, but without a strong catalyst or clear sustained trend data, probability is modest above the 0.5 threshold.

  150. !Jun 30, 5:46 PMsignal

    options_momentum — insufficient_capital

  151. !Jun 30, 5:31 PMsignal

    options_momentum — insufficient_capital

  152. ?Jun 30, 10:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.80% today, sitting just below the psychologically important $500 level at $497.29. The move is meaningful but not extreme — roughly 1.8% falls in the moderate range rather than a high-conviction flush. The single headline is a collaboration announcement (AustinPx/KinetiSol) that is marginally positive for TMO as a service provider, which slightly counters the downside narrative but is not a reversal catalyst. The macro backdrop is mildly supportive for long-duration sensitive names: 10Y inflation expectations are 1.7σ below trend (T10YIE at 2.22), which is generally a tailwind for growth/quality names like TMO via lower real rate pressure — this could support a stabilization or mild bounce. However, with 320 minutes remaining (a full trading day essentially still ahead), there is ample time for the move to extend, and the absence of a clear fundamental catalyst driving the decline leaves momentum ambiguous. The $500 level may provide some technical support that slows or stalls continuation. On balance, no strong reason to fade the move, but also no clear acceleration catalyst — rating this at the borderline threshold with a slight lean toward continuation given momentum bias and the system's risk parameters.

  153. ?Jun 29, 9:51 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 1.57% today, a moderate but not outsized move. The headline 'Gradually Getting Cheaper' is mildly bearish in framing — suggesting valuation compression is ongoing rather than a catalyst for reversal. The macro context shows T10YIE at 2.2, notably below trend (2.1σ), which is actually supportive of long-duration assets like high-quality growth/life science tools names — this creates a mild headwind to further downside continuation. The DHR headline is sector-adjacent noise with no direct TMO implication. With 355 minutes remaining (nearly a full session still ahead), there is ample time for the move to continue, but also for a mean reversion. The move magnitude (~1.57%) is real but not yet in the 2-5% conviction zone. No clear reversal pattern is evident, and the absence of a positive catalyst keeps the path of least resistance modestly lower. Overall this is a borderline read: slight lean toward continuation given the negative framing in headlines and lack of a bullish catalyst, but macro tailwinds from low inflation expectations temper confidence. Probability sits just above the 0.5 threshold.

  154. ✓Jun 24, 10:25 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    TMO is up 4.67% today, a meaningful move indicating real institutional flow. The headline referencing new analyst coverage (top life sciences tools stock) provides a modest catalyst narrative that supports the move. With 320 minutes remaining until the 3:45 PM cutoff, there is ample time for continuation. The macro backdrop is modestly supportive: T10YIE is running 2.0σ below its 24-month trend, meaning real yields and inflation expectations are compressed — this is a tailwind for long-duration, high-quality growth names like TMO which typically benefit from lower discount rates. No reversal signals or fade patterns are evident from the data provided. The absence of a blockbuster catalyst and the already-extended intraday move (4.67% is near the upper end of ordinary momentum) tempers enthusiasm — some profit-taking into the close is plausible — but the system's bounded risk profile (-1.5% stop, +3% target) makes this a reasonable long continuation setup. Probability held at 0.58 reflecting solid but not exceptional continuation pressure.

  155. ▢Jun 23, 8:00 PMjournal

    Agent 7 — Day Trader opened long 6 @ $491.27

  156. ▣Jun 23, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 6 @ $490.79 (-$2.85)

    EOD forced close — day trader never carries overnight

  157. ?Jun 9, 10:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is up 3.65% intraday, a meaningful move indicating real institutional flow and conviction. However, several factors temper enthusiasm for strong continuation: (1) HSBC downgrade/increased caution published overnight creates a known overhang — while the market has clearly absorbed some of this (or is ignoring it), it caps upside narrative and may attract profit-taking into the close; (2) the macro backdrop shows a flattening yield curve (T10Y2Y at 2-sigma below trend), which modestly favors defensives but TMO is more a growth/life-sciences name that can be pressured in bear-flattening environments; (3) 345 minutes remaining is ample time for continuation but also enough time for a fade if early buyers take profits; (4) no positive catalyst is identifiable — the move appears flow-driven, which is valid but less durable than a fundamental surprise. Balancing the raw momentum signal (3.65% moves do tend to have some follow-through statistically) against the analyst caution headline and neutral-to-mixed macro, a modest continuation probability above 0.5 is warranted but not a high-conviction setup.

  158. ?Jun 5, 2:55 PMdecisionconsidered

    Agent 7 — Day Trader — analyze: fail

    Claude analysis failed: Unexpected non-whitespace character after JSON at position 63 (line 6 column 1)

  159. ✓Jun 4, 9:05 AMdecisionacted

    Agent 7 — Day Trader — decide: buy

    TMO is down 1.69% today with a clear fundamental catalyst: HSBC downgrade published after yesterday's close. Downgrades from major institutional banks tend to generate multi-session selling as buy-side shops update models and reduce positions — the initial move often underestimates full repositioning pressure. The Cramer comment on Danaher (a life sciences peer) adds mild sector-level negative sentiment. The macro backdrop (T10Y2Y at 2.1σ below trend, bear-flattening) favors defensives broadly but TMO's growth/premium multiple makes it more sensitive to rate-driven derating narratives, not less. With 400 minutes remaining (well before the 3:45 cutoff), there is ample time for the downgrade-driven selling to continue into the close. No reversal signal is evident — this appears to be an orderly grind down rather than a sharp gap that could mean-revert. Probability set at 0.58: clear directional reason for continuation but move is moderate in size and macro tailwinds for defensives provide a partial offset.

  160. ?Jun 4, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    TMO is a fundamentally sound, high-quality life sciences tools company, and the 10.5% dip from its 30-day high appears to be largely sector-driven, as Health Care (XLV) is underperforming SPY by ~7.87pts over 30 days. However, the evidence base is extremely thin: no news headlines, no meaningful metrics in SEC filings, no insider activity, and no options flow to confirm an informed buying interest. The sector remains under persistent relative weakness with negative flow today (-$17M proxy), and the yield environment (10Y at 4.47%) adds a modest headwind for large-cap defensives.

  161. ?Jun 4, 7:02 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $2.80 cash available; close=$473.95.

  162. ▢Jun 3, 8:00 PMjournal

    Agent 7 — Day Trader opened short 3 @ $473.95

  163. ▣Jun 3, 8:00 PMjournalstop

    Agent 7 — Day Trader closed short 3 @ $481.73 (-$23.32)

    Short stop: close $481.73 ≥ stop $481.06

  164. ?Jun 3, 6:06 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    TMO is a fundamentally sound, high-quality life sciences tools company, and the 10.5% dip from its 30-day high appears to be largely sector-driven, as Health Care (XLV) is underperforming SPY by ~7.87pts over 30 days. However, the evidence base is extremely thin: no news headlines, no meaningful metrics in SEC filings, no insider activity, and no options flow to confirm an informed buying interest. The sector remains under persistent relative weakness with negative flow today (-$17M proxy), and the yield environment (10Y at 4.47%) adds a modest headwind for large-cap defensives.

  165. ?Jun 3, 6:05 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $3.84 cash available; close=$474.04.

  166. ✓Jun 3, 10:37 AMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    TMO (Thermo Fisher Scientific) is a high-quality life sciences tools and services company with a diversified revenue base and strong historical financial resilience. The 10.8% pullback from the 30-day high appears largely macro-driven — the yield curve (T10Y2Y at 0.42, 2σ below trend) signals a bear-flattening environment that pressures growth/defensives, and there are no news headlines indicating company-specific deterioration. The SEC filings (10-Q and 8-K) lack extracted metrics, but the absence of negative disclosures or guidance cuts is modestly reassuring.

  167. ✓Jun 3, 10:36 AMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    TMO (Thermo Fisher Scientific) is a high-quality life sciences tools and services company with a diversified revenue base and strong historical financial resilience. The 10.8% pullback from the 30-day high appears largely macro-driven — the yield curve (T10Y2Y at 0.42, 2σ below trend) signals a bear-flattening environment that pressures growth/defensives, and there are no news headlines indicating company-specific deterioration. The SEC filings (10-Q and 8-K) lack extracted metrics, but the absence of negative disclosures or guidance cuts is modestly reassuring.

  168. ?Jun 3, 9:06 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    TMO is down 2.42% intraday with no attributable headline, suggesting institutional selling or sector rotation rather than a news-driven spike. The macro backdrop shows a flat-to-slightly-inverted yield curve (T10Y2Y at 0.42, 2σ below trend), which is modestly supportive of defensive/healthcare names like TMO over the near term — this creates a mild headwind against further downside continuation. However, with 400 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for the move to continue or extend. A ~2.4% decline represents meaningful selling pressure and size-driven flow. In the absence of any reversal signals, news catalyst, or volume anomaly to suggest a fade, the base case leans toward modest continuation of the downtrend into the close. The yield curve context slightly tempers conviction, keeping this at a low-probability-continuation read rather than a high-conviction one.

  169. ?Jun 3, 7:02 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $2.42 cash available; close=$482.08.

  170. ?Jun 3, 7:02 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    TMO is a fundamentally sound, high-quality life sciences tools company, and the 10.5% dip from its 30-day high appears to be largely sector-driven, as Health Care (XLV) is underperforming SPY by ~7.87pts over 30 days. However, the evidence base is extremely thin: no news headlines, no meaningful metrics in SEC filings, no insider activity, and no options flow to confirm an informed buying interest. The sector remains under persistent relative weakness with negative flow today (-$17M proxy), and the yield environment (10Y at 4.47%) adds a modest headwind for large-cap defensives.

  171. ▢Jun 2, 8:00 PMjournal

    Agent 4 — Dip Buyer (Frozen) opened long 2 @ $473.88

  172. ?Jun 2, 6:04 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    TMO is a fundamentally sound, high-quality life sciences tools company, and the 10.5% dip from its 30-day high appears to be largely sector-driven, as Health Care (XLV) is underperforming SPY by ~7.87pts over 30 days. However, the evidence base is extremely thin: no news headlines, no meaningful metrics in SEC filings, no insider activity, and no options flow to confirm an informed buying interest. The sector remains under persistent relative weakness with negative flow today (-$17M proxy), and the yield environment (10Y at 4.47%) adds a modest headwind for large-cap defensives.

  173. ?Jun 2, 6:04 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash

    Wanted to buy but only $8.58 cash available; close=$482.01.

  174. ?Jun 2, 3:31 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 15 minutes remaining until the forced close, there is very limited runway for the move to continue meaningfully. TMO is already down 2.83%, a substantial intraday move, and at this late stage in the session, profit-taking and mean-reversion tendencies typically dominate — large institutional sellers who drove the move may be covering, and end-of-day rebalancing flows can stabilize or reverse the price. The macro context (T10Y2Y at 0.42, 2σ below trend) is modestly supportive of defensives like TMO's life sciences segment, which cuts against further downside. No headlines are present, meaning the move lacks a fresh catalyst to sustain into the final minutes. The combination of extreme time constraint, no new catalyst, and defensives-positive macro tilts the probability below 0.5 — this setup does not warrant a short position.

  175. ▢May 27, 8:00 PMjournal

    Agent 7 — Day Trader opened long 3 @ $478.70

  176. ▣May 27, 8:00 PMjournaltime_stop

    Agent 7 — Day Trader closed long 3 @ $485.81 (+$21.32)

    EOD forced close — day trader never carries overnight

← Back to dashboard